# Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

> **NCT00004879** · PHASE1 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Colorectal Cancer
- Esophageal Cancer
- Kidney Cancer
- Lung Cancer
- Pancreatic Cancer
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** panitumumab

## Key facts

- **NCT ID:** NCT00004879
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-04
- **Primary completion:** 2005-07
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2013-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004879, "Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00004879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*